High-throughput screening identifies established drugs as SARS-CoV-2 PLpro inhibitors
Protein & Cell
; (12): 877-888, 2021.
Article
de En
| WPRIM
| ID: wpr-922482
Bibliothèque responsable:
WPRO
ABSTRACT
A new coronavirus (SARS-CoV-2) has been identified as the etiologic agent for the COVID-19 outbreak. Currently, effective treatment options remain very limited for this disease; therefore, there is an urgent need to identify new anti-COVID-19 agents. In this study, we screened over 6,000 compounds that included approved drugs, drug candidates in clinical trials, and pharmacologically active compounds to identify leads that target the SARS-CoV-2 papain-like protease (PLpro). Together with main protease (M
Mots clés
Texte intégral:
1
Base de données:
WPRIM
Sujet principal:
Antiviraux
/
Inhibiteurs de protéases
/
Sites de fixation
/
Protéines recombinantes
/
Mutagenèse dirigée
/
Naphtoquinones
/
Structure tertiaire des protéines
/
Cristallographie aux rayons X
/
Concentration inhibitrice 50
/
Évaluation préclinique de médicament
Type d'étude:
Diagnostic_studies
/
Screening_studies
Limites:
Humans
Langue:
En
Journal:
Protein & Cell
Année:
2021
Type de document:
Article